Photo by bermixstudio from unsplash
In this issue of Blood, Rogers et al demonstrate that 3 novel agents approved for chronic lymphocytic leukemia (CLL), ibrutinib, venetoclax, and obinutuzumab, can be safely combined at standard doses… Click to show full abstract
In this issue of Blood, Rogers et al demonstrate that 3 novel agents approved for chronic lymphocytic leukemia (CLL), ibrutinib, venetoclax, and obinutuzumab, can be safely combined at standard doses to create an active, chemotherapy-free triplet regimen for relapsed or refractory disease.1
Keywords:
threat cll;
new triple;
triple threat
Journal Title: Blood
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!